VON ESCHENBACH ANDREW C.
VON ESCHENBACH ANDREW C.'s purchase track record
VON ESCHENBACH ANDREW C. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/27/2026 | BLCO | $80K | -14.5% | -6.3% | +12.1% |
| 5/2/2025 | BLCO | $20K | +17.4% | +29.9% | +20.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Transaction History
| BLCO | ▼ Sell | Open Market | 6,059 | $100K | 8/7/2026 | View on chart |
| BLCO | ▼ Sell | Open Market | 12,500 | $206K | 8/6/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 15,842 | $250K | 5/26/2026 | View on chart |
| BLCO | ▲ Buy | Open Market | 4,364 | $80K | 2/27/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 4,364 | $0 | 2/27/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 20,338 | $0 | 5/27/2025 | View on chart |
| BLCO | ▲ Buy | Open Market | 1,695 | $20K | 5/2/2025 | View on chart |
| BLCO | ▲ Buy | Grant | 14,696 | $0 | 8/2/2024 | View on chart |
| CELU | ▲ Buy | Grant | 199,921 | $0 | 6/14/2023 | View on chart |
| BLCO | ▲ Buy | Grant | 12,857 | $0 | 5/4/2023 | View on chart |
| CELU | ▲ Buy | Grant | 36,145 | $0 | 7/13/2022 | View on chart |
| BLCO | ▲ Buy | Grant | 12,500 | $0 | 5/10/2022 | View on chart |
| CELU | ▲ Buy | Option Exercise | 100,000 | $28K | 11/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting
Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.